In anticipation of its presentation at the J.P. Morgan Global Healthcare Conference, obesity drugmaker VIVUS (VVUS +0.00%) released its presentation in an SEC filing. Investors were particularly impressed with the improved prescription data for Qsymia, and shares jumped around 8% today on this news. In the following video, health care analyst Max Macaluso discusses this news, reasons for why Qsymia prescriptions are gaining momentum, and what this means for Arena Pharmaceuticals (ARNA +0.00%) -- VIVUS' main competitor in the obesity drug market.
Will VIVUS Prove Doubters Wrong?
By Max Macaluso – Jan 7, 2013 at 6:00PM
NASDAQ: VVUS
Vivus
Impressive prescription data from VIVUS today - is this a bigger threat than Arena thought?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo